<DOC>
	<DOC>NCT00162188</DOC>
	<brief_summary>This study is being conducted to assess the safety and tolerability of an oral liquid solution of Sustiva for antiretroviral therapy-naive or therapy-experienced HIV-1 infected children between the ages of 3-16 who are failing or intolerant of their current antiretroviral regimen and who are unable to swallow Sustiva capsules.</brief_summary>
	<brief_title>An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection: Canada</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<criteria>Children 316 years of age Antiretroviral naive or experienced Failing or intolerant to current antiretroviral (ARV) regimen Limited available viable therapeutic options Inability to take capsules/tablets Weighs less than 10 kg Failure on or concomitant use of other nonnucleoside reverse transcriptase inhibitors (NNRTIs) An active AIDSdefining opportunistic infection or disease More than two episodes of moderate to severe diarrhea or vomiting lasting more than four days within the past three months</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>